Recent Analysts’ Ratings Changes for Arvinas (ARVN)

Arvinas (NASDAQ: ARVN) has recently received a number of price target changes and ratings updates:

• 2/12/2025 – Arvinas had its price target raised by analysts at Oppenheimer Holdings Inc. from $40.00 to $45.00. They now have an “outperform” rating on the stock.
• 2/12/2025 – Arvinas had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $82.00 price target on the stock, down previously from $88.00.
• 2/12/2025 – Arvinas had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $57.00 price target on the stock.
• 2/12/2025 – Arvinas had its price target lowered by analysts at Stifel Nicolaus from $63.00 to $51.00. They now have a “buy” rating on the stock.
• 2/11/2025 – Arvinas had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.
• 2/7/2025 – Arvinas had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 2/3/2025 – Arvinas had its price target lowered by analysts at Barclays PLC from $48.00 to $32.00. They now have an “overweight” rating on the stock.

Arvinas Trading Up 3.6 %

Shares of ARVN traded up $0.64 on Monday, reaching $18.31. 935,305 shares of the company’s stock traded hands, compared to its average volume of 823,758. The stock’s 50 day simple moving average is $18.88 and its two-hundred day simple moving average is $23.16. The stock has a market cap of $1.26 billion, a PE ratio of -3.92 and a beta of 1.88. Arvinas, Inc. has a 52-week low of $16.61 and a 52-week high of $53.08.

Arvinas (NASDAQ:ARVN) last released its earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.44. During the same period in the prior year, the firm earned ($2.53) EPS. Analysts forecast that Arvinas, Inc. will post -3.22 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ARVN. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Arvinas by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock worth $61,000 after purchasing an additional 440 shares during the last quarter. Invesco Ltd. grew its holdings in Arvinas by 1.6% during the fourth quarter. Invesco Ltd. now owns 37,254 shares of the company’s stock valued at $714,000 after purchasing an additional 581 shares during the period. Rhumbline Advisers increased its position in Arvinas by 0.9% in the fourth quarter. Rhumbline Advisers now owns 87,877 shares of the company’s stock worth $1,685,000 after buying an additional 754 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Arvinas by 0.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 140,518 shares of the company’s stock valued at $2,694,000 after buying an additional 777 shares during the period. Finally, Bank of Montreal Can lifted its position in shares of Arvinas by 2.7% during the 4th quarter. Bank of Montreal Can now owns 39,407 shares of the company’s stock valued at $755,000 after buying an additional 1,044 shares during the last quarter. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.